• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Adverum Biotechnologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/18/25 8:00:26 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADVM alert in real time by email
    8-K
    NASDAQ false 0001501756 0001501756 2025-06-17 2025-06-17
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    June 17, 2025

    Date of Report (Date of earliest event reported)

     

     

    Adverum Biotechnologies, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-36579   20-5258327

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    100 Cardinal Way

    Redwood City, CA 94063

    (Address of principal executive offices, including zip code)

    (650) 656-9323

    (Registrant’s telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock   ADVM   Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐   

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Amended and Restated 2024 Equity Incentive Award Plan

    As discussed below in Item 5.07, Adverum Biotechnologies, Inc. (“Adverum”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) at which Adverum’s stockholders approved the amendment and restatement of Adverum’s 2024 Equity Incentive Award Plan (the “2024 Plan” and, as amended and restated, the “Amended 2024 Plan”).

    A summary of the material features of the Amended 2024 Plan is set forth in Adverum’s definitive proxy statement for the Annual Meeting, which was filed with the U.S. Securities and Exchange Commission on April 28, 2025 (as supplemented, the “Proxy Statement”). That summary is qualified in its entirety by reference to the full text of the Amended 2024 Plan, which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

    Repricing of Designated Underwater Options

    As discussed below in Item 5.07, at the Annual Meeting, Adverum’s stockholders approved the amendment of certain outstanding stock options. Effective as of June 17, 2025 (the “Effective Date”), the amendment reduces the exercise price per share of such options, as described in more detail in the Proxy Statement (such amendment, the “Repricing”).

    The Repricing applies to each option to purchase shares of Adverum’s common stock that: (a) was granted under Adverum’s 2014 Equity Incentive Award Plan, Adverum’s 2017 Inducement Plan or 2024 Plan; (b) was outstanding on the Effective Date; (c) as of the Effective Date, was held by an employee, or, to the extent designated by Adverum’s Board of Directors (the “Board”), was held by a consultant, in each case whose employment or service with Adverum and its subsidiaries and affiliates had not terminated as of the Effective Date (each, an “Eligible Participant”); and (d) had an exercise price per share that was, as of the Effective Date, higher than $10.14 (i.e., the prior 52-week intraday high trading price of Adverum’s common stock as of the Effective Date) (such options, the “Eligible Options”).

    The Eligible Options include underwater options held by each of Laurent Fischer, Adverum’s President and Chief Executive Officer (options to purchase 564,418 shares with original exercise prices ranging from $10.90 to $237.00); Linda Rubinstein, Adverum’s Chief Financial Officer (options to purchase 120,000 shares with original exercise prices ranging from $19.90 to $21.00); Rabia Gurses Ozden, Adverum’s Chief Medical Officer (options to purchase 12,000 shares with original exercise prices ranging from $13.50 to $15.60); Setareh Seyedkazemi, Adverum’s Chief Development Officer (options to purchase 91,000 shares with original exercise prices ranging from $12.90 to $19.90); and Kishor Peter Soparkar, Adverum’s Chief Operating Officer (options to purchase 197,048 shares with original exercise prices ranging from $10.90 to $157.50). Options held by non-employee members of the Board were not eligible for the Repricing.

    As of the Effective Date, the Eligible Options were repriced such that the exercise price per share for such options was reduced to $10.14, subject to certain retention requirements outlined below. If an Eligible Participant exercises an Eligible Option in advance of the end of the relevant Retention Period (as defined below), such Eligible Participant will be required to pay a premium exercise price equal to the original exercise price per share of such Eligible Option. There were no changes to the number of shares underlying the Eligible Options or to the vesting schedules or expiration dates of the Eligible Options as part of the Repricing.

    In order to exercise the Eligible Options at the reduced exercise price, Eligible Participants are required to remain in service with Adverum through the end of the relevant Retention Period (as hereinafter defined). The “Retention Period” begins on the Effective Date and ends on the earliest of the following: (i) the date 24 months following the Effective Date; (ii) a Change in Control (as defined in the 2024 Plan); and (iii) the Eligible Participant’s Termination of Service (as defined in the 2024 Plan) by reason of death or disability.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    On June 17, 2025, Adverum held the Annual Meeting. Stockholders who owned Adverum’s common stock at the close of business on April 21, 2025, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 20,890,576 shares of Adverum’s common stock were outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 16,886,434 shares of Adverum’s common stock were voted in person or by proxy for the proposals set forth below, each of which is described in the Proxy Statement.


    Proposal No. 1. Election of Directors

    Adverum’s stockholders elected the Class II director nominees below to the Board, each to hold office until the 2028 Annual Meeting of Stockholders and his successor is elected and has qualified, or until his earlier death, resignation or removal. The votes were as follows:

     

        

    Votes

    For

        

    Votes

    Withheld

         Broker Non-Votes  

    Laurent Fischer, M.D.

         11,629,888        1,085,648        4,170,898  

    Patrick Machado

         11,449,705        1,265,831        4,170,898  

    James Scopa

         11,720,019        995,517        4,170,898  

    Proposal No. 2. Ratification of Selection of Independent Registered Public Accounting Firm

    Adverum’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of Adverum for its fiscal year ending December 31, 2025. The votes were as follows:

     

    Votes For  

    Votes

    Against

      Abstentions
    16,353,263   20,296   512,875

    Proposal No. 3. Advisory Vote on Compensation of Named Executive Officers

    Adverum’s stockholders approved, on an advisory basis, the compensation of Adverum’s named executive officers as set forth in the Proxy Statement. The votes were as follows:

     

    Votes For  

    Votes

    Against

      Abstentions  

    Broker Non-

    Votes

    11,757,482   745,415   212,639   4,170,898

    Proposal No. 4. Approval of the Amendment and Restatement of the 2024 Plan

    Adverum’s stockholders approved the amendment and restatement of the 2024 Plan. The votes were as follows:

     

    Votes For  

    Votes

    Against

      Abstentions  

    Broker Non-

    Votes

    11,330,663   1,194,133   190,740   4,170,898

    Proposal No. 5. Approval of the Amendment of Certain Outstanding Stock Options to Reduce the Exercise Price Per Share as described in the Proxy Statement.

    Adverum’s stockholders approved the amendment of certain outstanding stock options to reduce the exercise price per share as described in the Proxy Statement. The votes were as follows:

     

    Votes For  

    Votes

    Against

      Abstentions  

    Broker Non-

    Votes

    9,442,652   3,064,709   208,175   4,170,898

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.

      

    Description

    10.1    Adverum Biotechnologies, Inc. 2024 Equity Incentive Award Plan, amended and restated effective June 17, 2025.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL Document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        ADVERUM BIOTECHNOLOGIES, INC.
    Date: June 18, 2025     By:  

    /s/ Laurent Fischer

         

    Laurent Fischer, M.D.

    President and Chief Executive Officer

    Get the next $ADVM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ADVM

    DatePrice TargetRatingAnalyst
    6/25/2024$25.00Outperform
    Oppenheimer
    4/30/2024$30.00Buy
    H.C. Wainwright
    7/7/2022$4.00Hold → Buy
    Truist
    7/23/2021Hold → Neutral
    Cantor Fitzgerald
    7/23/2021$23.00 → $3.00Overweight → Neutral
    Cantor Fitzgerald
    7/23/2021$5.00 → $2.00Market Perform
    SVB Leerink
    More analyst ratings

    $ADVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CHIEF OPERATING OFFICER Soparkar Peter

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      6/20/25 4:29:48 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CHIEF DEVELOPMENT OFFICER Seyedkazemi Setareh

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      6/20/25 4:29:06 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CHIEF FINANCIAL OFFICER Rubinstein Linda M

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      6/20/25 4:28:29 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    SEC Filings

    See more
    • SEC Form S-8 filed by Adverum Biotechnologies Inc.

      S-8 - Adverum Biotechnologies, Inc. (0001501756) (Filer)

      6/20/25 4:06:15 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Adverum Biotechnologies, Inc. (0001501756) (Filer)

      6/18/25 8:00:26 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Adverum Biotechnologies Inc.

      DEFA14A - Adverum Biotechnologies, Inc. (0001501756) (Filer)

      5/23/25 4:02:43 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Leadership Updates

    Live Leadership Updates

    See more
    • Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

      - 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H 2025 - $153.2 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter of 2024 and provided updates to anticipated milestones. "We remain laser focused on initiating

      11/4/24 4:39:45 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

      REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the launch strategy and building the commercial infrastructure for ixoberogene soroparvovec (Ixo-vec), Adverum's potential one-time intravitreal (IVT) injec

      10/16/24 8:00:00 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

      - 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable safety profile compared to OPTIC - LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024 - $173.8 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reporte

      8/12/24 4:05:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Financials

    Live finance-specific insights

    See more
    • Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

      REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The webcast will be held on Wednesday, July 17 at 8:00 a.m. ET and will include a presentation from Dr. Charles C. Wykoff, Director of Res

      7/10/24 8:00:00 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

      - Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET - REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related

      2/1/24 5:30:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

      REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. "We are very pleased to have the opportunity to present our initial Phase 2 efficacy and safety data from the LUNA study at the Macula Society meeting" stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. "We recently received confirmation that ou

      12/7/23 4:05:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4/A - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:31:52 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:24:13 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $1,048,950 worth of shares (350,000 units at $3.00), increasing direct ownership by 35% to 191,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/24/25 9:35:07 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Adverum Biotech with a new price target

      Oppenheimer initiated coverage of Adverum Biotech with a rating of Outperform and set a new price target of $25.00

      6/25/24 8:10:21 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Adverum Biotech with a new price target

      H.C. Wainwright initiated coverage of Adverum Biotech with a rating of Buy and set a new price target of $30.00

      4/30/24 6:15:49 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotech upgraded by Truist with a new price target

      Truist upgraded Adverum Biotech from Hold to Buy and set a new price target of $4.00

      7/7/22 7:11:07 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream

      MIAMI, July 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 84th Emerging Growth Conference on July 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, July 16, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go

      7/16/25 7:00:00 AM ET
      $ADVM
      $ASPI
      $BNZI
      $CLNN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Chemicals
      Industrials
    • Presenting on Emerging Growth Conference 84 Day 1 on July 16; Register to live stream

      MIAMI, July 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 84th Emerging Growth Conference on July 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1July 16, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the registra

      7/15/25 7:00:00 AM ET
      $ADVM
      $ASPI
      $BNZI
      $CLNN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Chemicals
      Industrials
    • Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 9,740 shares of common stock and restricted stock units (RSUs) for 4,870 shares of common stock to two new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $2.22 per share, equal to the per share closing price of Adverum's common st

      6/5/25 4:01:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

      SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      11/14/24 6:57:12 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

      SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      11/14/24 6:40:56 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

      SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      11/14/24 4:05:12 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care